Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 2/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753360 | 0.84 | CSNK1A1 (0.42) | CSNK1A1TYRO3DYRK1BALDH1A1TDP1 | |
| SCHEMBL30163620 | 0.84 | TDP1 (0.42) | CSNK1A1TYRO3DYRK1BALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL11732214 | 0.83 | GAA (0.46) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL5249670 | 0.81 | MAPT (0.56) | ALDH1A1TDP1GAAMEN1KMT2A | |
| SCHEMBL8537593 | 0.80 | GSK3B (0.47) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL8536034 | 0.80 | ESR1 (0.43) | CSNK1A1TYRO3DYRK1BALDH1A1GAA | |
| SCHEMBL8540810 | 0.80 | TSHR (0.50) | ALDH1A1GAANISCHMEN1KMT2A | |
| SCHEMBL5528175 | 0.80 | S100A4 (0.46) | CSNK1A1TYRO3DYRK1BALDH1A1MTOR | |
| SCHEMBL8542469 | 0.78 | TSHR (0.49) | CSNK1A1TYRO3DYRK1BALDH1A1GAA | |
| SCHEMBL8541098 | 0.78 | TDP1 (0.47) | CSNK1A1TYRO3DYRK1BTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101735217-B | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug | UNIV GUANGDONG PHARM | 2012-09-26 | — | — | CN | claimed |
| CN-101863894-B | Tanshinone II A derivative and preparation method and application thereof | UNIV GUANGDONG PHARM | 2012-07-18 | — | — | CN | claimed |
| US-8053762-B2 | Imidazoquinazoline derivative, process for preparing the same, and organic electronic device using the same | LG CHEM, LTD. (KR) | 2011-11-08 | — | — | US | claimed |
| WO-2007069847-A9 | NOVEL IMIDAZOQUINAZOLINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM. LTD. (KR) | 2010-12-16 | — | — | WO | claimed |
| CN-101863894-A | Tanshinone II A derivative and preparation method and application thereof | GUANGDONG PHARMACEUTICAL UNIVERSITY | 2010-10-20 | — | — | CN | claimed |
| CN-101735217-A | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug | UNIV GUANGDONG PHARM | 2010-06-16 | — | — | CN | claimed |
| EP-1960402-A1 | NOVEL IMIDAZOQUINAZOLINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG Chem, Ltd. (KR) | 2008-08-27 | — | — | EP | claimed |
| WO-2007069847-A1 | NOVEL IMIDAZOQUINAZOLINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM. LTD. (KR) | 2007-06-21 | — | — | WO | claimed |
| US-20070131929-A1 | Novel imidazoquinazoline derivative, process for preparing the same, and organic electronic device using the same | LG CHEM. LTD. (KR) | 2007-06-14 | — | — | US | claimed |
| WO-2003027117-A1 | A PROCESS FOR THE PREPARATION OF 5-(SUBSTITUTED)-10-METHOXY-2,2,4-TRIMETHYL-2,5-DIHYDRO-1H-CHROMENO[3,4-F]QUINOLINES AND DERIVATIVES THEREOF | ABBOTT LABORATORIES (US) | 2003-04-03 | — | — | WO | claimed |
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS LLC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS LLC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-1751118-B1 | PYRIMIDINES FOR USE AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-12-03 | — | — | EP | disclosed |
| CN-101316853-B | Benzothiazole and thiazolopyridine as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC | 2014-09-24 | — | — | CN | disclosed |
| CN-103145738-A | Imidazo [2,1-b] thiayole derivatives as SIRTUIN modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2013-06-12 | — | — | CN | disclosed |
| US-4534790-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
| US-4465505-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0083975-A2 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-07-20 | — | — | EP | disclosed |
| EP-0070181-A1 | Silver halide light-sensitive color photographic material | KONICA CORPORATION (JP) | 1983-01-19 | — | — | EP | disclosed |
| EP-0046446-A1 | Polyazaheterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | VHL, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CSNK1A1 1959/4885TYRO3 1391/4885DYRK1B 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.